• A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

  NCT06633783

  Not yet recruitingInterventionalPhase 3Updated Oct 9, 2024
• Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

  NCT07036172

  RecruitingInterventionalPhase 3Updated Jun 25, 2025
• Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

  NCT07150975

  RecruitingInterventionalPhase 3Updated Nov 25, 2025
• Semaglutide in Treatment of Obesity

  NCT06604624

  CompletedInterventionalPhase 3Updated Apr 6, 2026
• A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

  NCT05579249

  CompletedInterventionalPhase 4Updated Jan 14, 2026
• A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

  NCT07285902

  Active, not recruitingInterventionalPhase 3Updated Feb 27, 2026

ClinicalTrials.gov ID

NCT06738979

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

408Estimated

Last Update Posted

Dec 18, 2024Actual

Start Date

Mar 2025Estimated

Primary Completion Date

Jul 2026Estimated

Completion Date

Aug 2026Estimated

Official Title

A Multicenter, Randomized, Open, Parallel Controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Brief Summary

This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in obese subjects (BMI≥28 kg/m2).

Equivalence tests were performed for the percentage (%) of weight loss at 44w relative to baseline at the primary endpoint. A meta-analysis was performed based on multiple registration studies of the original drug Wegovy® (semaglutide), and the final equivalence threshold was determined (-4.16%, 4.16%). It was assumed that the sample size ratio of the experimental group and the control group was 1:1, the overall difference between the experimental group and the control group was 0, the standard deviation of the reference original drug was 11%, and the degree of assurance (1-β) was 85%. Double unilateral t test was adopted, and double unilateral α=0.025. The sample size was 326 cases by the Power Analysis & Sample Size (PASS) 2019 Software. Considering the 20% shedding rate, 408 patients were enrolled in this study, 204 in each group.

• Obesity

• TQF3510 (Semaglutide Injection)
• Wegovy®

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age 18-70 years old, gender is not limited;
• Body mass index (BMI) ≥ 28 kg/m2;
• Self-report at least one unsuccessful diet and weight loss history;
• Patients must give informed consent to this study before the trial and sign the informed consent voluntarily.

Exclusion Criteria:

• Pregnant or lactating women or men or women of childbearing age who had a pregnancy plan during the study period (including a spouse), or who refused to take the contraceptive measures specified in the programme during the study period;

• Have a history of diabetes of any type;

• Patients who had used any hypoglycemic drugs within 90 days before screening;

• Personal or first-degree relatives have a personal or family history of thyroid C-cell tumor or multiple endocrine tumor syndrome type 2;

• Use of any drugs for weight management within 90 days prior to screening;

• Previous or planned weight loss related treatment through surgery or other weight loss means during the study period;

• Have a history of major depression or serious mental illness;

• Mental Health Scale (PHQ-9) score ≥ 15 during screening;

• History of acute pancreatitis within 180 days prior to screening;

• Have a history of chronic pancreatitis or pancreatic surgery;

• Laboratory tests during screening meet any of the following criteria:

  1. Alanine aminotransferase (ALT)> 2.5× upper limit of normal (ULN), aspartate aminotransferase (AST)>2.5 ULN;
  2. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2;
  3. calcitonin ≥ 50 ng/L (pg/mL);
  4. Triglyceride (TG) ≥500 mg/dl (5.7mmol/L);
  5. Thyroid stimulating hormone (TSH) >6 mIU/L or <0.4 mIU/L.

• When virological tests at the time of screening show any of the following:

  1. Hepatitis C virus (HCV) antibody positive, and HCV virus titer detection value exceeds the upper limit of normal value;
  2. HBsAg positive and Hepatitis B virus (HBV) DNA test value exceeds the upper limit of normal value;
  3. HIV positive;
  4. Active syphilis: the screening period of treponema pallidum antibody positive and non-Treponema pallidum serum test (RPR or TRUST) positive;

• Uncontrolled or poorly treated hypertension;

• Clinically significant cardiovascular and cerebrovascular disease in the 6 months prior to screening;

• People who are allergic to Semaglutide injection or any component of Wegovy®, or to other GLP-1 receptor agonists, or who have a pre-existing allergic disorder;

• Participated in any other clinical trial within 3 months prior to screening;

• The subject is unable to comply with the treatment plan and diet and exercise plan established by the investigator;

• There are secondary causes affecting body weight;

• There is hypothyroidism at the time of screening that is not controlled with stable drug dosages;

• Have a history of major surgery within 6 months prior to screening;

• A history of drug abuse or alcohol dependence within the 6 months prior to screening;

• History of malignant tumor within 5 years before screening;

• Patients with other diseases that the researchers assessed would affect the safety of the subjects, affect the efficacy evaluation or compliance, or other conditions that the researchers considered unsuitable for enrollment.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

2658836019@qq.com15856306039

1521710470@qq.com13559925729

wjy7496@qq.com13919842516

185301748@qq.com19976160915

13977418927@163.com13977418927

ljr_lcsy@163.com13315777123

dzywhf@163.com18632009978

fanghui2818@126.com13831581838

tiandezeng@126.com13949500187

sunwp07@163.com18607328933

1766990886@qq.com13812050092

1324240153@qq.com13901527177

Xucr126@126.com15162120096

mwlj521@126.com18112009828

986816730@qq.com15979872886

13869123309@163.com15318816218

19xiaodong@163.com18678186512

2601307515@qq.com18008258775

gtl52@163.com13567288210

pengfei_du@126.com13957391756

yh7115@126.com13566163203